SXTCNasdaqPharmaceutical PreparationsFiscal year ends March 31
China SXT Pharmaceuticals, Inc.
Financials through fiscal 2026, year ended Mar 31, 2026Last filing: 20-F on Jul 1, 2026
$0.11+0.05 (+71.08%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
China SXT Pharmaceuticals, Inc. revenue by segment
By business segment
By product or service
| Revenue | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|
| Revenues generated from third parties | $1.14M | $1.74M | $1.90M | $1.94M | $2.26M | 100.0% | -34.5% |
| Regular TCMP [Member] | $1.08M | $1.44M | – | – | – | 95.0% | -25.0% |
| Advanced TCMP [Member] | $49.52K | $258.42K | – | – | – | 4.4% | -80.8% |
| Others [Member] | $7.14K | $40.03K | – | – | – | 0.6% | -82.2% |
| Revenue generated from related parties | $41 | $4.30K | $27.76K | $33.62K | $339.13K | 0.0% | -99.0% |
By region
From the segment and revenue-disaggregation notes of China SXT Pharmaceuticals's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.